A new study published in Nature found that people with a specific genetic variant may see better results from GLP-1 weight-loss drugs like Ozempic and Mounjaro. This research could help doctors predict which patients are most likely to benefit from these medications.
Posts tagged as “new research”
Some people don't lose significant weight on GLP-1 medications, and genetics may explain why they're "non-responders." However, new research shows these drugs still provide important health benefits like improved heart health, even without major weight loss.
New research suggests GLP-1 medications provide health benefits beyond weight loss, including reduced risk of heart attacks and strokes. Even patients who don't lose significant weight may still gain important cardiovascular protection from these drugs.
A new study found that people with a specific genetic variant may respond better to GLP-1 weight loss drugs like Ozempic and Wegovy. This discovery could help predict which patients will see the most success with these medications.
Millions of Americans are experimenting with GLP-1 medications for various purposes, but scientific research hasn't caught up to understand all the effects. This widespread use is happening faster than studies can be conducted to fully evaluate safety and effectiveness.
Millions of Americans are using GLP-1 weight loss drugs like Ozempic, but scientific research hasn't caught up to understand all the effects. This widespread real-world use is happening faster than formal studies can track safety and effectiveness.
Stanford researchers discovered a compound that mimics Ozempic's weight loss effects without common side effects in mice studies. The treatment caused 3 grams of weight loss primarily from fat, with no changes in movement, digestion, or anxiety-like behaviors.
While most people lose weight on GLP-1 medications, new research shows these drugs may provide health benefits even for those who don't shed pounds. The medications appear to have positive effects beyond just weight reduction.